Kane Biotech (KNE) Q1 2025 earnings summary

Executive summary

• Revenue for Q1 2025 reached $412,513, a significant increase from $51,886 in Q1 2024, primarily from contract animal health manufacturing for Dechra Veterinary Products.

• Gross profit was $42,447, slightly up from $40,051 year-over-year.

• Net loss narrowed to $1,218,497 from $1,346,825 in the prior year quarter.

• Restructuring strategy initiated, focusing on the revyve™ wound care product portfolio and cost reduction.

Financial highlights

• Operating expenses for Q1 2025 were $1,203,505, down from $1,228,153 in Q1 2024.

• Revenue growth driven by new contract manufacturing agreements.

• Cost reduction initiatives implemented to lower monthly operating costs.

Outlook and guidance

• Strategic focus on US commercial opportunities and the revyve™ product line.

• Continued execution of restructuring and cost-saving measures to preserve cash.